• ipharmaservices

FDA approved AbbVie’s Rinvoq for treatment of moderately to severe rheumatoid arthritis

AbbVie has announced that FDA has approved Rinvoq (upadacitinib) for the treatment of moderate to severe rheumatoid arthritis who have inadequate or intolerant to methotrexate. Upadacitnib is oral JAK inhibitor.

The approval is based on the SELECT trial, the largest Phase 3 trial in the field of rheumatoid arthritis. Safety, efficacy, and tolerability were assessed in 4,400 across all treatment arms in five studies.


SELECT-EARLY

  • After 12 weeks, 52% patient on upadacitinib achieved ACR50 vs. 28% in patients on methotrexate

  • 36% of patients achieved clinical remission compared to 14% in patients on methotrexate

SELECT-MONOTHERAPY

  • After 14 weeks, 65% of MTX-IR patients achieved ACR20 who are in upadacitinib vs 41% in patients who continued the treatment with methotrexate

  • 30% of patients reported clinical remission

SELECT-COMPARE

  • After 12 weeks, 71% MTX-IR patients achieved ACR20 in Rinvoq + MTX arm vs 36% in patients on placebo + csDMARDs

  • 30% of patients reported clinical remission

SELECT-NEXT

  • After 12 weeks, 64% of csDMARD-IR patients achieved ACR20 who were treated with Rinvoq vs. 36% in patients on placebo + csDMARD

SELECT-BEYOND

  • After 12 weeks, 65% of biologic-IR patients achieved ACR20 who were treated with Rinvoq + csDMARD vs. 28% in patients with placebo + csDMARD

The adverse effects reported were upper respiratory tract infections, nausea, cough, and pyrexia.

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices